Comparison of Alternative Androgen Receptor-axis-targeted Agent (ARATA) and Docetaxel as Second-line Therapy for Patients With Metastatic Castration-resistant Prostate Cancer With Progression After Initial ARATA in Real-world Clinical Practice in Japan

Second Line Therapy ◽

Castration Resistant ◽

Line Therapy ◽

Targeted Agent

MP52-12 COMPARISON OF ALTERNATIVE ANDROGEN RECEPTOR-AXIS-TARGETED AGENT (ARATA) VERSUS DOCETAXEL AS SECOND-LINE THERAPY FOR PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PROGRESSING AFTER INITIAL ARATA IN REAL-WORLD CLINICAL PRACTICE IN JAPAN

The Journal of Urology ◽

10.1016/j.juro.2018.02.1663 ◽

2018 ◽

Vol 199 (4S) ◽

Author(s):

Yuto Matsushita ◽

Keita Tamura ◽

Takayuki Sugiyama ◽

Hideaki Miyake

Keyword(s):

Prostate Cancer ◽

Clinical Practice ◽

Androgen Receptor ◽

Real World ◽

Second Line ◽

Second Line Therapy ◽

Castration Resistant ◽

Line Therapy ◽

Targeted Agent

Androgen receptor (AR) activation levels on circulating tumor cells (CTCs) to predict response to second-line therapy in castration-resistant prostate cancer (CRPC)

Science-Business eXchange ◽

10.1038/scibx.2012.1168 ◽

2012 ◽

Vol 5 (44) ◽

pp. 1168-1168

Keyword(s):

Prostate Cancer ◽

Androgen Receptor ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Second Line ◽

Second Line Therapy ◽

Castration Resistant ◽

Cabazitaxel and prednisone as second-line therapy of metastatic, castration-resistant prostate cancer

Community Oncology ◽

10.1016/s1548-5315(11)70531-9 ◽

2010 ◽

Vol 7 (12) ◽

pp. 540-542 ◽

Cited By ~ 1

Author(s):

Jame Abraham

Keyword(s):

Prostate Cancer ◽

Second Line ◽

Second Line Therapy ◽

Castration Resistant ◽

Second-line therapy in patients with metastatic castration-resistant prostate cancer with progression after or under docetaxel: A systematic review of nine randomized controlled trials

Seminars in Oncology ◽

10.1053/j.seminoncol.2017.10.005 ◽

2017 ◽

Vol 44 (5) ◽

pp. 358-371 ◽

Cited By ~ 7

Author(s):

Michiel H.F. Poorthuis ◽

Robin W.M. Vernooij ◽

R. Jeroen. A. van Moorselaar ◽

Theo M. de Reijke

Keyword(s):

Prostate Cancer ◽

Systematic Review ◽

Randomized Controlled Trials ◽

Controlled Trials ◽

Second Line ◽

Second Line Therapy ◽

Randomized Controlled ◽

Castration Resistant ◽

Role of free testosterone levels in patients with metastatic castration-resistant prostate cancer receiving second-line therapy

Oncology Letters ◽

10.3892/ol.2016.5392 ◽

2016 ◽

Vol 13 (1) ◽

pp. 22-28 ◽

Cited By ~ 6

Author(s):

Christoph A. von Klot ◽

Markus A. Kuczyk ◽

Alena Boeker ◽

Christoph Reuter ◽

Florian Imkamp ◽

...

Keyword(s):

Prostate Cancer ◽

Free Testosterone ◽

Second Line ◽

Second Line Therapy ◽

Testosterone Levels ◽

Castration Resistant ◽

Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor-targeted agent (ARTA) following early progression on a first-line ARTA in a US community oncology setting

Urologic Oncology Seminars and Original Investigations ◽

10.1016/j.urolonc.2018.08.002 ◽

2018 ◽

Vol 36 (11) ◽

pp. 500.e1-500.e9 ◽

Cited By ~ 11

Author(s):

William K. Oh ◽

Wendy Y. Cheng ◽

Raymond Miao ◽

Francis Vekeman ◽

Marjolaine Gauthier-Loiselle ◽

...

Keyword(s):

Prostate Cancer ◽

Androgen Receptor ◽

Second Line ◽

First Line ◽

Castration Resistant ◽

Community Oncology ◽

Early Progression ◽

Targeted Agent ◽

Line Chemotherapy

CARD: A randomized phase 4 trial comparing cabazitaxel and an androgen receptor (AR)-targeted agent in men with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and an alternative AR-targeted agent

Annals of Oncology ◽

10.1093/annonc/mdw372.50 ◽

2016 ◽

Vol 27 ◽

pp. vi262

Author(s):

R. de Wit ◽

K. Fizazi ◽

E. Efstathiou ◽

R. Dittamore ◽

S. Hitier ◽

...

Keyword(s):

Prostate Cancer ◽

Androgen Receptor ◽

Castration Resistant ◽

Targeted Agent

Real-world Characteristics and Outcomes of Patients With Metastatic Castration-resistant Prostate Cancer Receiving Chemotherapy Versus Androgen Receptor-targeted Therapy After Failure of First-line Androgen Receptor-targeted Therapy in the Community Setting

Clinical Genitourinary Cancer ◽

10.1016/j.clgc.2017.06.004 ◽

2018 ◽

Vol 16 (1) ◽

pp. 50-57 ◽

Cited By ~ 11

Author(s):

William K. Oh ◽

Raymond Miao ◽

Francis Vekeman ◽

Jennifer Sung ◽

Wendy Y. Cheng ◽

...

Keyword(s):

Prostate Cancer ◽

Androgen Receptor ◽

Targeted Therapy ◽

Real World ◽

Community Setting ◽

First Line ◽

Castration Resistant

Reply to Julie Steinestel, Christof Bernemann, Andres J. Schrader, and Jochen K. Lennerz's Letter to the Editor re: Emmanuel S. Antonarakis, Changxue Lu, Brandon Luber, et al. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men with Metastatic Castration-resistant Prostate Cancer Treated with First- and Second-line Abiraterone and Enzalutamide. J Clin Oncol 2017;35:2149–56. AR-V7 Testing: What's in it for the Patient?

European Urology ◽

10.1016/j.eururo.2017.06.032 ◽

2017 ◽

Vol 72 (6) ◽

pp. e170-e171 ◽

Cited By ~ 1

Author(s):

Jun Luo ◽

Brandon Luber ◽

Hao Wang ◽

Emmanuel S. Antonarakis

Keyword(s):

Prostate Cancer ◽

Androgen Receptor ◽

Clin Oncol ◽

Tumor Cells ◽

Clinical Significance ◽

Splice Variant ◽

Second Line ◽

Castration Resistant ◽

Androgen Receptor Splice Variant

ANDROGEN RECEPTOR GENE AMPLIFICATION AT PRIMARY PROGRESSION PREDICTS RESPONSE TO COMBINED ANDROGEN BLOCKADE AS SECOND LINE THERAPY FOR ADVANCED PROSTATE CANCER

The Journal of Urology ◽

10.1097/00005392-200012000-00029 ◽

2000 ◽

pp. 1992-1995 ◽

Cited By ~ 4

Author(s):

C. PALMBERG ◽

P. KOIVISTO ◽

L. KAKKOLA ◽

T. L. J. TAMMELA ◽

O. P. KALLIONIEMI ◽

...

Keyword(s):

Prostate Cancer ◽

Androgen Receptor ◽

Advanced Prostate Cancer ◽

Receptor Gene ◽

Androgen Receptor Gene ◽

Second Line ◽

Second Line Therapy ◽

Combined Androgen Blockade ◽

Line Therapy ◽

Androgen Blockade